Interestingly, it has been recently reported that small molecule inhibitors of NRF2 pathway sensitize cancer cells carrying KEAP1 mutants to chemotherapy59 and that inhibition of SKP2 sensitizes lung cancer cells to paclitaxel60,61. Here, SKP2 is linked to lung carcinoma.